Back to search
FDAFDA · Food and drugs·Recall number D-1132-2018

Valsartan Tablets, USP 160 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-785-15 Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Published September 5, 2018 · Recall initiated: August 14, 2018

Summary

FDA records drug Class II recall D-1132-2018, published September 5, 2018 and initiated August 14, 2018. Recalling firm: AVKARE Inc.; Status: Terminated; Reported quantity: 818 cartons (40,900 tablets); Lot: Lots: 17717 Exp. 07/2018; 18493 Exp. 01/2019; 19761 Exp. 04/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AVKARE Inc.
Distributor
U.S. Nationwide
Lot
Lots: 17717 Exp. 07/2018; 18493 Exp. 01/2019; 19761 Exp. 04/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Valsartan Tablets, USP 160 mg Rx Only 50 Tablets (5x10) Unit Dose NDC 50268-785-15 Manufactured for: AvKARE, Inc. Pulaski, TN 38478 recalled?

Yes. FDA published recall D-1132-2018 on September 5, 2018. Reported hazard: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter